Cancer Research UK has awarded nearly £60 million in funding to three US investigator-led research initiatives focused on cancer progression and drug response.
Research continues to show that it is possible to detect genetic signs of cancer in a blood sample without the need to measure specific oncogenic mutations.
Led by investigators at the University of Trento in Italy, the team received a five-year, £5 million ($6.4 million) award recently to advance its work.